首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1907989

比美珠單抗市場：依適應症、年齡層、性別、最終用戶、通路和地區分類

Bimekizumab Market, By Indication, By Age Group, By Gender, By End User, By Distribution Channel, By Geography

出版日期: 2025年12月19日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2025 年，bimekizumab 市場規模將達到 15.2 億美元，預計到 2032 年將達到 56.1 億美元，2025 年至 2032 年的複合年成長率為 20.5%。

報告覆蓋範圍		報告詳情
基準年：	2024	2025年市場規模：	15.2億美元
歷史數據時期：	2020年至2024年	預測期：	2025年至2032年
預測期（2025-2032年）複合年成長率：	20.50%	2032 年的預測值：	56.1億美元

全球比美珠單抗市場是生物製藥行業中一個快速發展的細分市場，其核心是新型單株抗體療法，該療法能夠選擇性地抑制白細胞介素-17A和白細胞介素-17F兩種細胞激素。作為一種創新免疫調節劑，比美珠單抗已成為治療多種自體免疫發炎疾病（尤其是乾癬、乾癬性關節炎、僵直性脊椎炎及其他相關發炎性疾病）的極具前景的治療選擇。這種雙重抑制IL-17A/F的機制使比美珠單抗區別於現有的IL-17抑制劑，有望提高治療效果並改善患者預後。

市場成長的主要驅動力是全球自體免疫疾病盛行率的不斷上升、人們對先進生物療法的認知度不斷提高以及對標靶免疫療法解決方案需求的不斷成長。主要醫藥市場監管機構的核准已使bimekizumab成為生物治療市場的重要競爭者。製藥業對精準醫療和個人化治療方案的持續關注也進一步加速了市場接受度。與傳統的單標靶治療相比，醫療服務提供者越來越認知到雙重細胞激素抑制的潛在優勢，這有助於擴大臨床應用範圍，並提高市場滲透率，惠及尋求有效長期控制慢性發炎性疾病的各類患者群體。

市場動態

全球比美珠單抗市場正經歷強勁成長，其主要促進因素包括銀屑病、乾癬性關節炎和僵直性脊椎炎自體免疫疾病在全球範圍內的日益普及。這些疾病共影響數百萬患者，因此亟需有效的治療方法。臨床試驗中展現出的卓越療效，尤其是其雙重IL-17A/F抑制機制（與單靶點競爭藥物相比，該機制顯著提升了治療效果），是推動市場成長的關鍵因素。此外，醫療保健支出不斷成長以及生物製藥療法的日益普及也促進了市場發展。醫療專業人員對先進免疫調節療法的認知不斷提高，診斷能力的不斷提升，以及已開發市場有利的報銷政策，都為患者提供了便利。

然而，市場成長仍面臨諸多限制因素。生物製藥的高昂成本限制了其可近性，尤其是在醫療預算有限的新興經濟體。此外，嚴格的監管核准流程需要大量的臨床證據，潛在的安全隱患（例如免疫抑制導致的感染風險增加）以及來自現有IL-17抑制劑和其他替代生物療法的激烈競爭也是挑戰。單株抗體的生產複雜性和供應鏈挑戰也構成營運方面的阻礙因素。

然而，隨著適應症擴展到目前正在進行臨床試驗的其他自體免疫疾病，隨著醫療基礎設施的改善，新興經濟體的市場滲透率不斷提高，聯合治療的開發可能改善治療效果，更加注重個性化醫療方法，以及專利到期後生物類似藥的潛在開發，這些都帶來了巨大的機遇，從而使更廣泛的患者群體能夠獲得市場准入和負擔得起。

本次調查的主要特點

本報告對全球比美珠單抗市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）內的市場規模（十億美元）和復合年成長率（%）。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
該研究根據以下參數對全球 Bimekizumab 市場的主要企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本研究涵蓋的主要企業包括 UCB。
本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
這份全球比美珠單抗市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過全球 Bimekizumab 市場分析中使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

第11章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9110

Bimekizumab Market is estimated to be valued at USD 1.52 Bn in 2025 and is expected to reach USD 5.61 Bn by 2032, growing at a compound annual growth rate (CAGR) of 20.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1.52 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	20.50%	2032 Value Projection:	USD 5.61 Bn

Global bimekizumab market represents a rapidly evolving segment within biopharmaceutical industry, centered around a novel monoclonal antibody therapeutic that selectively inhibits both interleukin-17A and interleukin-17F cytokines. Bimekizumab, developed as an innovative immunomodulatory agent, has emerged as a promising treatment option for various autoimmune inflammatory conditions, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and other related inflammatory disorders. This dual IL-17A/F inhibition mechanism distinguishes bimekizumab from existing IL-17 inhibitors, potentially offering enhanced therapeutic efficacy and improved patient outcomes.

The market's growth trajectory is primarily driven by increasing prevalence of autoimmune diseases globally, rising awareness about advanced biologic therapies, and growing demand for targeted immunotherapy solutions. Regulatory approvals across major pharmaceutical markets have positioned bimekizumab as a significant competitor in the biologic therapeutics landscape. The pharmaceutical industry's continued focus on precision medicine and personalized treatment approaches has further accelerated market adoption. Healthcare providers increasingly recognize the potential benefits of dual cytokine inhibition compared to traditional single-target therapies, contributing to expanding clinical applications and market penetration across diverse patient populations seeking effective long-term management of chronic inflammatory conditions.

Market Dynamics

The global bimekizumab market experiences robust growth driven by several key factors, including the escalating worldwide prevalence of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, which collectively affect millions of patients seeking effective treatment alternatives. The superior efficacy profile demonstrated in clinical trials, particularly the dual IL-17A/F inhibition mechanism that provides enhanced therapeutic outcomes compared to single-target competitors, serves as a primary market driver alongside increasing healthcare expenditure and growing adoption of biologic therapies. Rising awareness among healthcare professionals about advanced immunomodulatory treatments and expanding diagnostic capabilities contribute to market expansion, while favorable reimbursement policies in developed markets facilitate patient access.

However, market growth faces significant restraints including the exceptionally high cost of biologic therapies that limits accessibility, particularly in emerging economies with constrained healthcare budgets, stringent regulatory approval processes requiring extensive clinical evidence, potential safety concerns associated with immunosuppression including increased infection risks, and intense competition from established IL-17 inhibitors and other biologic alternatives. Manufacturing complexities and supply chain challenges for monoclonal antibodies also pose operational constraints.

Nevertheless, substantial opportunities emerge through expanding applications to additional autoimmune indications currently under clinical investigation, growing market penetration in emerging economies with improving healthcare infrastructure, development of combination therapies that could enhance treatment outcomes, increasing focus on personalized medicine approaches, and potential biosimilar development following patent expiration that could improve market accessibility and affordability for broader patient populations.

Key Features of the Study

This report provides in-depth analysis of the global bimekizumab market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bimekizumab market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key company covered as a part of this study include UCB
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bimekizumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bimekizumab market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Plaque Psoriasis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Non-radiographic axial spondyloarthritis (nraxSpA)
- Other Investigational Autoimmune Indications
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Dermatology Clinics
- Rheumatology Clinics
- Specialty Care Centers
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- UCB

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Bimekizumab Market, By Indication
- Global Bimekizumab Market, By Age Group
- Global Bimekizumab Market, By Gender
- Global Bimekizumab Market, By End User
- Global Bimekizumab Market, By Distribution Channel
- Global Bimekizumab Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Bimekizumab Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Plaque Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Non-radiographic axial spondyloarthritis (nraxSpA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Investigational Autoimmune Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Bimekizumab Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bimekizumab Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bimekizumab Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Dermatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rheumatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Bimekizumab Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Bimekizumab Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa